Quality of Clinical Care at Burjeel Medical City, Abu Dhabi

Stay Updated with the Latest Developments at Burjeel Medical City

Quality of Clinical Care at Burjeel Medical City, Abu Dhabi

Quality of Clinical Care at Burjeel Medical City, Abu Dhabi

Indicator Performance

0.02

Benchmark

0.2

Infection

Multiple Drug Resistance Blood Stream Infection

MDRO

Preventing the Spread of Resistance: Strengthening Our Infection Control Culture


With an overall rate of 0.02 per 1,000 inpatient days, we remain well below the CDC benchmark of 0.2 — demonstrating the effectiveness of our robust infection prevention strategies and commitment to controlling antimicrobial resistance.

Indicator Performance

0

Benchmark

0.5

Infection

healthcare associated infection (HAI) Clostridium Difficile Infection (CDI)

HAI-CDI

Near-Zero Infection Rates: Sustaining Excellence in CDI Prevention


With a Clostridium difficile infection (CDI) rate of 0 per 1,000 inpatient days, we continue to exceed the CDC benchmark of 0.5 — reflecting our unwavering commitment to infection control and patient safety.

Indicator Performance

1.13

Benchmark

3.1

Embolism

Perioperative Pulmonary Embolism (PE)or Deep Vein Thrombosis (DVT)

DVT

Exceeding National Standards: Ensuring Safer Surgical Outcomes


With a PE/DVT rate of 1.13 per 1,000 surgical discharges, we significantly outperform the AHRQ benchmark of 3.1 — highlighting our strong adherence to surgical safety protocols and excellence in postoperative care.

Indicator Performance

3.1%

Benchmark

10-15%

Readmission

30-day unplanned hospital readmission rate for medical and surgical patients

Readmission

Supporting Recovery Beyond Discharge


With an overall readmission rate of 3.1% per 100 adult discharges, we remain well within our internal goal of keeping readmissions below the 10% threshold — demonstrating our commitment to safe transitions of care and sustained recovery.

Indicator Performance

89%

Benchmark

90%

Access To Care

Hospital Wait at Point of Arrival (Minutes)

Waiting Time

Improving Access: Our Ongoing Commitment to Timely Care

In 2024, 89% of patients were seen within 60 minutes — closely aligning with the Department of Health (DOH) benchmark of 90%, reflecting our continuous efforts to enhance timely access to care.

Indicator Performance

99%

Benchmark

90%

Specialist Access

Consultant or specialist Hospital Appointment (excluding cancer) (Days)

Appointment

Timely Specialist Access: A System-Wide Success


In 2024, 99% of patients across the system were seen within 14 working days , significantly exceeding the Department of Health (DOH) benchmark of 90%.

Indicator Performance

90%

Benchmark

90%

Emergency Waiting Time

Seeing a doctor in Accident and Emergency (Minutes)

Emergency Time

Delivering Timely Emergency Care When It Matters Most


In 2024, 90% of patients were seen by a doctor within 60 minutes — reflecting continued progress toward achieving the Department of Health’s 90% benchmark through focused enhancements in patient flow and service delivery.

Indicator Performance

1.7%

Benchmark

3%

Re-Attendance

24 hours – Re attendance rate to Accident and Emergency Department

Emergency

Right Care the First Time: Reducing Unplanned Returns


With a re-attendance rate of just 1.7%, we remain well within our internal target of keeping unplanned returns below 3% — reinforcing our commitment to delivering effective and timely emergency care.

Indicator Performance

0.1%

Benchmark

3%

Incomplete Visit

Left Without Being Seen (LWBS) by an Emergency Department Doctor

LWBS

Keeping Patients Engaged in Their Emergency Care Journey


Only 0.1% of patients left before being assessed — well within the Department of Health (DOH) benchmark of 3%, reflecting our continued commitment to timely care and an improved patient experience in the emergency department.

Diagnosed with Breast Cancer During Pregnancy, Mother of Four Welcomes Baby While Undergoing Chemotherapy 

Diagnosed with Breast Cancer During Pregnancy, Mother of Four Welcomes Baby While Undergoing Chemotherapy 

Diagnosed with stage III breast cancer five months into pregnancy, Samar received

Learn More
Burjeel Medical City Introduces the Gulf’s First Chronic Sinusitis Treatment Administered Once Every Six Months   

Burjeel Medical City Introduces the Gulf’s First Chronic Sinusitis Treatment Administered Once Every Six Months   

The injection was given to a 43-year-old Emirati male patient who had

Learn More
Four Burjeel Holdings Hospitals Recognized in Newsweek’s World’s Best Hospitals & Clinics for Medical Tourism 2027 

Four Burjeel Holdings Hospitals Recognized in Newsweek’s World’s Best Hospitals & Clinics for Medical Tourism 2027 

Three of the nine recognized institutions in Abu Dhabi are part of

Learn More
Burjeel Holdings’ AiMed Solutions and Proximie to Co-Develop Next-Generation of Intelligent Operating Rooms that Understand and Predict 

Burjeel Holdings’ AiMed Solutions and Proximie to Co-Develop Next-Generation of Intelligent Operating Rooms that Understand and Predict 

Signed at the Abu Dhabi Future Health Summit 2026, the collaboration brings

Learn More
Burjeel Training Academy, NYU Abu Dhabi Partner to Advance Healthcare Research, Innovation, and Talent Development 

Burjeel Training Academy, NYU Abu Dhabi Partner to Advance Healthcare Research, Innovation, and Talent Development 

Signed on the sidelines of the Abu Dhabi Future Health Summit 2026,

Learn More
Burjeel Hospital Partners with South Korea’s ARPI to Advance AI-Powered Cardiac Diagnostics 

Burjeel Hospital Partners with South Korea’s ARPI to Advance AI-Powered Cardiac Diagnostics 

Signed at the Abu Dhabi Future Health Summit 2026, the agreement will

Learn More
Burjeel Holdings and UK-Based Avatrial Join Hands to Develop First-of-Its-Kind AI-Powered Cancer Drug Discovery Ecosystem in Abu Dhabi 

Burjeel Holdings and UK-Based Avatrial Join Hands to Develop First-of-Its-Kind AI-Powered Cancer Drug Discovery Ecosystem in Abu Dhabi 

Signed at the Abu Dhabi Future Health Summit, the UK–UAE collaboration aims

Learn More
Burjeel Cancer Institute in Abu Dhabi introduces targeted radiopharmaceutical therapy for certain metastatic tumours 

Burjeel Cancer Institute in Abu Dhabi introduces targeted radiopharmaceutical therapy for certain metastatic tumours 

Abu Dhabi, 16 October 2026: Burjeel Cancer Institute has introduced therapeutic radiopharmaceuticals

Learn More
Call Now Appointment